Endeavour announces positive Feasibility Study for its Ity CIL project
Nov 10, 2016 11:54 am UTC| Business
George Town, Grand Cayman, United Kingdom, Nov. 10, 2016 -- Endeavour announces positive Feasibility Study for its Ity CIL project ...
Selecta Biosciences Receives Exclusive Rights to Peanut Allergy and Celiac Disease Programs
Nov 10, 2016 11:45 am UTC| Business
WATERTOWN, Mass., Nov. 10, 2016 -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune therapies, today announced that it is...
Sanchez Production Partners LP Announces Public Offering of Common Units
Nov 10, 2016 11:36 am UTC| Business
HOUSTON, Nov. 10, 2016 -- Sanchez Production Partners LP (NYSE MKT:SPP) (“SPP” or the “Partnership”) today announced that it has commenced an underwritten public offering of 8,823,529 common units representing limited...
Auris Medical Provides Business Update and Reports Third Quarter 2016 Financial Results
Nov 10, 2016 11:30 am UTC| Business
AM-111 Phase 3 program for acute inner ear hearing loss is ongoing Amended TACTT3 trial of KeyzilenTM provides clear path forward for acute inner ear tinnitus program Conference call today at 8 am Eastern Time ZUG,...
Superconductor Technologies Reports 2016 Third Quarter Results
Nov 10, 2016 11:30 am UTC| Business
AUSTIN, Texas, Nov. 10, 2016 -- Superconductor Technologies Inc. (STI) (Nasdaq:SCON) reported financial results for the quarter ended Oct.1, 2016. “In the third quarter, STI’s HTS wire program focused on demonstrating...
Histogenics Corporation Announces Third Quarter 2016 Financial and Operating Results
Nov 10, 2016 11:30 am UTC| Business
- NeoCart® Phase 3 Clinical Trial More than 75% Enrolled -- Enrollment On-Track to Complete by End of Second Quarter of 2017 -- Third Quarter Financing Expected to Fund Company to Phase 3 Data -- Company to Host Conference...
Adaptimmune Reports Third Quarter 2016 Financial Results
Nov 10, 2016 11:30 am UTC| Business
– U.S. Food and Drug Administration (FDA) lifted partial clinical hold of myxoid/round cell liposarcoma (MRCLS) study of NY-ESO SPEAR™ T-cell therapy; initiation of screening expected in 4Q 2016 – – Initiated first site...